Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

Michael D. Green, James L. Speyer, James C. Wernz, Nicoletta Colombo, Uziel Beller, Franco M. Muggia, E. Mark Beckman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

Original languageEnglish
Pages (from-to)333-336
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number3
DOIs
Publication statusPublished - Aug 1990

Fingerprint

Anthracyclines
Ovarian Neoplasms
Neutropenia
Thrombocytopenia
Nausea
Vomiting
esorubicin
Pharmaceutical Preparations
Population

Keywords

  • 4′ deoxydoxorubicin
  • anthracycline
  • clinical trial
  • esorubicin
  • ovarian cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. / Green, Michael D.; Speyer, James L.; Wernz, James C.; Colombo, Nicoletta; Beller, Uziel; Muggia, Franco M.; Beckman, E. Mark.

In: Investigational New Drugs, Vol. 8, No. 3, 08.1990, p. 333-336.

Research output: Contribution to journalArticle

Green, Michael D. ; Speyer, James L. ; Wernz, James C. ; Colombo, Nicoletta ; Beller, Uziel ; Muggia, Franco M. ; Beckman, E. Mark. / Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer. In: Investigational New Drugs. 1990 ; Vol. 8, No. 3. pp. 333-336.
@article{3b8ece4ed0a447dd8ee954f4977bd992,
title = "Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer",
abstract = "Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.",
keywords = "4′ deoxydoxorubicin, anthracycline, clinical trial, esorubicin, ovarian cancer",
author = "Green, {Michael D.} and Speyer, {James L.} and Wernz, {James C.} and Nicoletta Colombo and Uziel Beller and Muggia, {Franco M.} and Beckman, {E. Mark}",
year = "1990",
month = "8",
doi = "10.1007/BF00171850",
language = "English",
volume = "8",
pages = "333--336",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

AU - Green, Michael D.

AU - Speyer, James L.

AU - Wernz, James C.

AU - Colombo, Nicoletta

AU - Beller, Uziel

AU - Muggia, Franco M.

AU - Beckman, E. Mark

PY - 1990/8

Y1 - 1990/8

N2 - Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

AB - Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

KW - 4′ deoxydoxorubicin

KW - anthracycline

KW - clinical trial

KW - esorubicin

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0025071555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025071555&partnerID=8YFLogxK

U2 - 10.1007/BF00171850

DO - 10.1007/BF00171850

M3 - Article

C2 - 2272774

AN - SCOPUS:0025071555

VL - 8

SP - 333

EP - 336

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -